BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fourrier C, Sampson E, Mills NT, Baune BT. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo. Trials 2018;19:447. [PMID: 30126458 DOI: 10.1186/s13063-018-2829-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Ye Z, Kappelmann N, Moser S, Davey Smith G, Burgess S, Jones PB, Khandaker GM. Role of inflammation in depression and anxiety: Tests for disorder specificity, linearity and potential causality of association in the UK Biobank. EClinicalMedicine 2021;38:100992. [PMID: 34505025 DOI: 10.1016/j.eclinm.2021.100992] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Feng X, Fan Y, Chung CY. Mefenamic acid can attenuate depressive symptoms by suppressing microglia activation induced upon chronic stress. Brain Res 2020;1740:146846. [PMID: 32325074 DOI: 10.1016/j.brainres.2020.146846] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Nikkheslat N. Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency. Brain Behav Immun Health 2021;18:100383. [PMID: 34849492 DOI: 10.1016/j.bbih.2021.100383] [Reference Citation Analysis]
4 Mills NT, Sampson E, Fourrier C, Baune BT. Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial. Int J Neuropsychopharmacol 2021;24:314-21. [PMID: 33269395 DOI: 10.1093/ijnp/pyaa092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Bennabi D, Haffen E, Van Waes V. Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research. Front Psychiatry 2019;10:771. [PMID: 31780961 DOI: 10.3389/fpsyt.2019.00771] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
6 Atique-ur-rehman H, Neill JC. Cognitive dysfunction in major depression: From assessment to novel therapies. Pharmacology & Therapeutics 2019;202:53-71. [DOI: 10.1016/j.pharmthera.2019.05.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
7 Brown PJ, Ciarleglio A, Roose SP, Garcia CM, Chung S, Alvarez J, Stein A, Gomez S, Rutherford BR. Frailty Worsens Antidepressant Treatment Outcomes in Late Life Depression. Am J Geriatr Psychiatry 2021;29:944-55. [PMID: 33388223 DOI: 10.1016/j.jagp.2020.12.024] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Forbes MP, O'Neil A, Lane M, Agustini B, Myles N, Berk M. Major Depressive Disorder in Older Patients as an Inflammatory Disorder: Implications for the Pharmacological Management of Geriatric Depression. Drugs Aging 2021;38:451-67. [PMID: 33913114 DOI: 10.1007/s40266-021-00858-2] [Reference Citation Analysis]
9 Wisłowska-Stanek A, Kołosowska K, Maciejak P. Neurobiological Basis of Increased Risk for Suicidal Behaviour. Cells 2021;10:2519. [PMID: 34685499 DOI: 10.3390/cells10102519] [Reference Citation Analysis]
10 Nadalin S, Jakovac H, Peitl V, Karlović D, Buretić-Tomljanović A. Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review). Mol Med Rep 2021;24:611. [PMID: 34184073 DOI: 10.3892/mmr.2021.12250] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Adamo D, Pecoraro G, Coppola N, Calabria E, Aria M, Mignogna M. Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open-label randomized trial. Oral Dis 2021;27:1022-41. [PMID: 32790904 DOI: 10.1111/odi.13602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Knight MJ, Mills NT, Baune BT. Contemporary methods of improving cognitive dysfunction in clinical depression. Expert Review of Neurotherapeutics 2019;19:431-43. [DOI: 10.1080/14737175.2019.1610395] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
13 di Michele F, Talamo A, Niolu C, Siracusano A. Vitamin D and N-Acetyl Cysteine Supplementation in Treatment-Resistant Depressive Disorder Patients: A General Review. CPD 2020;26:2442-59. [DOI: 10.2174/1381612826666200406090051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Brás JP, Pinto S, Almeida MI, Prata J, von Doellinger O, Coelho R, Barbosa MA, Santos SG. Peripheral Biomarkers of Inflammation in Depression: Evidence from Animal Models and Clinical Studies. Methods Mol Biol 2019;2011:467-92. [PMID: 31273717 DOI: 10.1007/978-1-4939-9554-7_28] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Samodien E, Johnson R, Pheiffer C, Mabasa L, Erasmus M, Louw J, Chellan N. Diet-induced hypothalamic dysfunction and metabolic disease, and the therapeutic potential of polyphenols. Mol Metab 2019;27:1-10. [PMID: 31300352 DOI: 10.1016/j.molmet.2019.06.022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
16 Fourrier C, Sampson E, Hori H, Schubert KO, Clark S, Mills NT, Baune BT. Exploratory study of association between blood immune markers and cognitive symptom severity in major depressive disorder: Stratification by body mass index status. Brain, Behavior, and Immunity 2020;88:242-51. [DOI: 10.1016/j.bbi.2020.06.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 De Diego-Adeliño J, Crespo JM, Mora F, Neyra A, Iborra P, Gutiérrez-Rojas L, Salonia SF. Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. Expert Opin Drug Saf 2021;:1-18. [PMID: 34964415 DOI: 10.1080/14740338.2022.2019705] [Reference Citation Analysis]
18 Branchi I, Poggini S, Capuron L, Benedetti F, Poletti S, Tamouza R, Drexhage HA, Penninx BWJH, Pariante CM; European College of Neuropsychopharmacology (ECNP) ImmunoNeuroPsychiatry Thematic Working Group and Marion Leboyer. Brain-immune crosstalk in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2021;45:89-107. [PMID: 33386229 DOI: 10.1016/j.euroneuro.2020.11.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
19 Westwell-Roper C, Stewart SE. Commentary: Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders. Front Psychiatry 2020;11:264. [PMID: 32425818 DOI: 10.3389/fpsyt.2020.00264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Herder C, Hermanns N. Subclinical inflammation and depressive symptoms in patients with type 1 and type 2 diabetes. Semin Immunopathol 2019;41:477-89. [PMID: 30778653 DOI: 10.1007/s00281-019-00730-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
21 Knight MJ, Aboustate N, Baune BT. Cognitive Dysfunction in Major Depressive Disorder: Cause and Effect. Curr Behav Neurosci Rep 2018;5:302-9. [DOI: 10.1007/s40473-018-0160-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
22 Baune BT, Sampson E, Louise J, Hori H, Schubert KO, Clark SR, Mills NT, Fourrier C. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial. Eur Neuropsychopharmacol 2021;53:34-46. [PMID: 34375789 DOI: 10.1016/j.euroneuro.2021.07.092] [Reference Citation Analysis]